Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 548d-1 (MIR548D1) is a small (20–24 nucleotides), non-coding RNA belonging to the microRNA family, encoded in the human genome and transcribed by RNA polymerase II[2]. It is processed from a primary transcript via Drosha and Dicer into a mature miRNA, which associates with the RNA-induced silencing complex (RISC) to regulate diverse target mRNAs, typically resulting in translational repression or mRNA destabilization[2]. MIR548D1 is implicated in the regulation of cell proliferation, survival, apoptosis, and participates in several critical signaling pathways. It has experimentally observed or predicted roles in tumorigenesis, including in breast, colorectal, lung cancers, and has been identified as a possible player in neuronal and somatic diseases[1][2]. Computational studies suggest its sequence may also inhibit flavivirus (e.g., hepatitis C virus, dengue, zika) capsid gene expression, with early-stage bioinformatic evidence pointing towards antiviral therapeutic potential, though this is preclinical[1]. As a microRNA, it is not a classic "drug target" receptor or enzyme, but may be investigated therapeutically via RNA-based strategies or as a biomarker[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 548d-1 (MIR548D1).